PMID- 33179144
OWN - NLM
STAT- MEDLINE
DCOM- 20210924
LR  - 20211204
IS  - 1559-0267 (Electronic)
IS  - 1080-0549 (Linking)
VI  - 60
IP  - 1
DP  - 2021 Feb
TI  - Immunometabolic Pathways and Its Therapeutic Implication in Autoimmune Diseases.
PG  - 55-67
LID - 10.1007/s12016-020-08821-6 [doi]
AB  - Autoimmune diseases (AIDs) are characterized with aberrant immune responses and 
      their respective signaling pathways controlling cell differentiation, death, and 
      survival. Cell metabolism is also an indispensable biochemical process that 
      provides the very fundamental energy and materials. Accumulating evidences 
      implicate that metabolism pathways have critical roles in determining the 
      function of different immune subsets. Mechanisms of how immunometabolism 
      participate in the pathogenesis of AIDs were also under intensive exploration. 
      Here, in this review, we summarize the metabolic features of immune cells in AIDs 
      and also the individual function of immunometabolism pathways, including glucose 
      metabolism and tricarboxylic acid (TCA) cycle, in the setting of AIDs, mainly 
      focusing on the potential targets for intervention. We also review studies that 
      explore the intervention strategies targeting key molecules of metabolic 
      pathways, such as mammalian target of rapamycin (mTOR), AMP-activated protein 
      kinase (AMPK), and hypoxia-inducible factor 1a (HIF1a), in systemic lupus 
      erythematosus (SLE) and rheumatoid arthritis (RA). The highlight of this review 
      is to provide a comprehensive summary of the status quo of immunometabolism 
      studies in AIDs and the potential translatable drug targets.
FAU - Wang, Tingting
AU  - Wang T
AD  - Department of Medical Research Center, Peking Union Medical College Hospital, 
      Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, 
      100730, China.
AD  - Clinical Immunology Centre, Medical Epigenetics Research Centre, State Key 
      Laboratory of Difficult and Severe and Rare Diseases, Peking Union Medical 
      College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical 
      College, Beijing , 100730, China.
AD  - State Key Laboratory of Difficult, Severe and Rare Diseases, Peking Union Medical 
      College Hospital, Peking Union Medical College and Chinese Academy of Medical 
      Sciences, Beijing , 100730, China.
FAU - Jiao, Yuhao
AU  - Jiao Y
AD  - Clinical Immunology Centre, Medical Epigenetics Research Centre, State Key 
      Laboratory of Difficult and Severe and Rare Diseases, Peking Union Medical 
      College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical 
      College, Beijing , 100730, China.
AD  - Department of Rheumatology and Clinical Immunology, Peking Union Medical College 
      Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; 
      The Ministry of Education Key Laboratory, Beijing , 100730, China.
FAU - Zhang, Xuan
AU  - Zhang X
AUID- ORCID: 0000-0001-8775-1699
AD  - Clinical Immunology Centre, Medical Epigenetics Research Centre, State Key 
      Laboratory of Difficult and Severe and Rare Diseases, Peking Union Medical 
      College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical 
      College, Beijing , 100730, China. zxpumch2003@sina.com.
AD  - Department of Rheumatology and Clinical Immunology, Peking Union Medical College 
      Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; 
      The Ministry of Education Key Laboratory, Beijing , 100730, China. 
      zxpumch2003@sina.com.
AD  - State Key Laboratory of Difficult, Severe and Rare Diseases, Peking Union Medical 
      College Hospital, Peking Union Medical College and Chinese Academy of Medical 
      Sciences, Beijing , 100730, China. zxpumch2003@sina.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201112
PL  - United States
TA  - Clin Rev Allergy Immunol
JT  - Clinical reviews in allergy & immunology
JID - 9504368
RN  - 0 (HIF1A protein, human)
RN  - 0 (Hypoxia-Inducible Factor 1, alpha Subunit)
RN  - EC 2.7.- (Protein Kinases)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - EC 2.7.11.3 (AMP-Activated Protein Kinase Kinases)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
EIN - Clin Rev Allergy Immunol. 2020 Nov 27;:. PMID: 33245482
MH  - AMP-Activated Protein Kinase Kinases
MH  - Animals
MH  - Autoimmune Diseases/immunology/*metabolism
MH  - Citric Acid Cycle
MH  - Glucose/*metabolism
MH  - Humans
MH  - Hypoxia-Inducible Factor 1, alpha Subunit/metabolism
MH  - Metabolic Networks and Pathways/*immunology
MH  - Molecular Targeted Therapy
MH  - Protein Kinases/metabolism
MH  - Signal Transduction
MH  - TOR Serine-Threonine Kinases/metabolism
OTO - NOTNLM
OT  - Autoimmune diseases
OT  - Glycolysis
OT  - Metabolism
OT  - TCA cycle
OT  - Therapeutic target
EDAT- 2020/11/13 06:00
MHDA- 2021/09/25 06:00
CRDT- 2020/11/12 05:46
PHST- 2020/11/02 00:00 [accepted]
PHST- 2020/11/13 06:00 [pubmed]
PHST- 2021/09/25 06:00 [medline]
PHST- 2020/11/12 05:46 [entrez]
AID - 10.1007/s12016-020-08821-6 [pii]
AID - 10.1007/s12016-020-08821-6 [doi]
PST - ppublish
SO  - Clin Rev Allergy Immunol. 2021 Feb;60(1):55-67. doi: 10.1007/s12016-020-08821-6. 
      Epub 2020 Nov 12.